The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1071
February 7, 2000
View Complete Issue         Table of Contents 2019 
Aggrenox: A Combination of Antiplatelet Drugs for Stroke Prevention
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Aggrenox: A Combination of Antiplatelet Drugs for Stroke Prevention
February 7, 2000 (Issue: 1071)
Aggrenox, a fixed-dose oral combination of aspirin and extended-release dipyridamole, is now being advertised for secondary prevention of a transient ischemic attack (TIA) or ischemic stroke.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Aggrenox: A Combination of Antiplatelet Drugs for Stroke Prevention
Article code: 1071a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.